

Supporting Information

The Discovery of a Potent Small-Molecule Antagonist of cIAP1/2 and XIAP Proteins and Clinical Candidate for the Treatment of Cancer (GDC-0152)

John A. Flygare,^{,†} Maureen Beresini,[‡] Nageshwar Budha,[#] Helen Chan,[|] Iris T. Chan,[⊥] Sravanthi Cheeti,[#] Frederick Cohen,[†] Kurt Deshayes,[§] Karl Doerner,[¶] S. Gail Eckhardt,[⋆] Linda O. Elliott,[‡] Bainian Feng,[†] Matthew C. Franklin,[§] Stacy Frankovitz Reisner,[‡] Lewis Gazzard,[†] Jason Halladay,[|] Sarah G. Hymowitz,[◇] Hank La,[|] Patricia LoRusso,[∇] Brigitte Maurer,[◇] Lesley Murray,[¶] Emile Plise,[|] Clifford Quan,[§] Jean-Philippe Stephan,[‡] Young G. Shin,[|] Jeffrey Tom,[§] Vickie Tsui,[†] Joanne Um,[†] Eugene Varfolomeev,[§] Domagoj Vucic,[§] Andrew J. Wagner,[∞] Heidi J.A. Wallweber,[◇] Lan Wang,[†] Joseph Ware,[#] Zhaoyang Wen,[†] Harvey Wong,[|] Jonathan M. Wong,[†] Melisa Wong,[†] Susan Wong,[|] Ron Yu,[▽] Kerry Zobel,[§] and Wayne J. Fairbrother^{*,§}*

Table of Contents

X-ray data collection and refinement statistics (Table S1) – 2

Summary of clinical pharmacokinetics parameters for **1** from Day 1 Cycle 1 (Table S2) – 3

Immunoprecipitation and immunoblotting of melanoma SK-MEL28 cells (Figure S1) – 4

Table S1. X-ray data collection and refinement statistics

Protein Construct	ML-IAP/XIAP chimera	cIAP1/XIAP chimera
	(MLXBIR3SG)	(cXBIR3CS)
Resolution (Å)	50 – 1.71 (1.75 – 1.71)	31.36 – 1.79 (1.83 – 1.79)
Space Group	P4 ₁ 2 ₁ 2	P2 ₁ 2 ₁ 2 ₁
Unit cell (Å)	a = 87.4, c = 73.5	a = 35.7, b = 37.4, c = 57.6
Unique reflections	29,746 (2,145)	6,767 (369)
R _{sym} ^b	0.055 (0.346)	0.085 (0.467)
<I/σ(I)>	32.9 (5.7)	13 (2.5)
Redundancy	7.9 (8.0)	3.3 (3.3)
R _{cryst} ^c	0.154	0.177
R _{free} ^d	0.162	0.230
Bond RMSD (Å)	0.007	0.011
Angle RMSD (°)	1.1	1.5

^a Numbers in parentheses are for the highest resolution shell. ^b $R_{\text{sym}} = \frac{\sum_{hkl} |I - \langle I \rangle|}{\sum_{hkl} I}$.

^c $R_{\text{cryst}} = \frac{\sum_{hkl} \|F_{(\text{obs})} - F_{(\text{calc})}\|}{\sum_{hkl} |F_{(\text{obs})}|}$. ^d $R_{\text{free}} = R_{\text{cryst}}$ for a random 5% (MLXBIR3SG) or 10% (cXBIR3CS) of reflections.

Table S2. Summary of clinical pharmacokinetics parameters for Compound **1** from Day 1 of

Cycle 1

Cohort	Dose (mg/kg)		Terminal Half-Life (hr)	C _{max} (μM)	AUC _∞ (μM·hr)	CL (mL/min/kg)	V _{ss} (L/kg)
1	0.049	N	2	2	2	2	2
		Mean	3.8	0.18	0.13	20	1.0
		CV%	40	6.5	10	21	12
2	0.1	N	3	3	3	3	3
		Mean	4.4	0.55	0.36	10.8	0.6
		CV%	28	67	44	40	62
3	0.2	N	4	4	4	4	4
		Mean	4.2	1.1	0.84	10.7	0.7
		CV%	11	24	25	35	51
4	0.28	N	3	3	3	3	3
		Mean	3.4	1.4	1.2	12.0	0.6
		CV%	15	35	28	17	22
5	0.39	N	5	5	5	5	5
		Mean	4.0	1.6	1.4	12.2	0.8
		CV%	12	33	37	36	34
6	0.54	N	4	4	4	4	4
		Mean	3.9	3.6	2.7	10.3	0.6
		CV%	7	101	65	55	72
7	0.76	N	11	11	11	11	11
		Mean	4.1	3.3	2.8	11.6	0.7
		CV%	10	27	23	22	40
8	1.06	N	3	3	3	3	3
		Mean	3.7	6.3	5.2	10.2	0.7
		CV%	10	67	42	42	47
9	1.48	N	1	1	1	1	1
		Mean	3.9	7.0	6.8	11.3	0.8
		CV%	na	na	na	na	na




Figure S1. SK-MEL28 cells were treated with Gemcitabine (0.5 μ M) and compound **1** (0.5 μ M) for 20 h in the presence of the caspase inhibitor, zVAD (10 μ M). At that time the cells were lysed in NP40 lysis buffer, immunoprecipitated with the anti-Smac antibody, resolved on SDS-PAGE, and immunoprecipitates (top panel) and total cell lysates (bottom two panels) were immuno-blotted with anti-ML-IAP and anti-Smac antibodies.